A clinical trial investigating the safety and effectiveness of tirzepatide taken once weekly compared to insulin taken once daily in people with type 2 diabetes and increased cardiovascular risk.
About this study
The primary purpose of the study aims to address the following questions:
- Whether tirzepatide can help study participants with type 2 diabetes
- The safety of tirzepatide and any side effects when taken
- How much tirzepatide should be given to study participants
- How tirzepatide compares to insulin glargine
Anticipated enrolment close date: November 2019
Who can take part
You may be eligible to take part in this study if:
- You have been diagnosed with type 2 diabetes
- You are aged 18 years or over
- Have known cardiovascular disease
- Your blood glucose levels could be better
- You do not currently administer your diabetes medication via an injection
- Blood and urine samples
- Height and weight
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.